Search results
AstraZeneca’s Fasenra: Approval for asthma may initiate COPD approval
Pharmaceutical Technology via Yahoo Finance· 7 days agoAccording to leading data and analytics company GlobalData’s...reduce exacerbations and manage the...
Regeneron Reverses On Better-Than-Feared Eylea Sales
Investor's Business Daily· 4 days agoHigh-dose Eylea came in at $200 million, beating expectations for $189 million, Leerink Partners analyst David Risinger said in a report. The high dose...
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
Morningstar· 5 days agoSociety (ATS) 2024 International Conference taking place May 12-22 in San Diego. "We look forward to presenting encouraging data from our Phase 2a COURSE trial in COPD with ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 4 days agoPDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024
Earnings call: Regeneron reports steady growth, prepares for new launches By Investing.com
Investing.com· 4 days agoThis growth was primarily driven by strong sales of Dupixent and Libtayo, as well as collaboration...
Plant-based diet may reduce risk of emphysema among smokers - UPI.com
UPI· 7 days agoCurrent and former smokers might lower their risk for emphysema if they adopt a highly nutritional...
Mesothelioma
Health· 3 days agoRelated conditions include: Chronic obstructive pulmonary disease (COPD): Affects your breathing ability and blocks airflow Coronary artery disease...
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
GuruFocus.com via Yahoo Finance· 3 days agoRegeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi's sBLA for Dupixent for COPD treatment was accepted by the FDA for priority review, highlighting ...
Viemed Healthcare (VMD) to Release Earnings on Tuesday
ETF DAILY NEWS· 8 hours agoViemed Healthcare (NASDAQ:VMD – Get Free Report) is scheduled to announce its earnings results before the market opens on Tuesday, May 7th. Viemed Healthcare has set its Q1 2024 guidance at ...
AstraZeneca to present respiratory disease research at ATS 2024 By Investing.com
Investing.com· 5 days agoDiego, California. The pharmaceutical company announced today that it will showcase 59 abstracts,...